NASDAQ · Healthcare
Invest in AC Immune stock from India
Indian and foreign residents can buy AC Immune (ACIU) shares directly through Paasa.
By Paasa · Updated
AC Immune at a glance
- Price
- $2.72+$0.12 (4.42%)
- Market cap
- $276.32M
- Day range
- $2.61 – $2.75
- P/E
- -5.26
- Dividend yield
- None
- Volume
- 86.50K
- 1 month
- +2.45%
- 6 months
- +0.56%
- YTD
- -13.54%
- 1 year
- -10.69%
- 5 years
- -59.54%
AC Immune statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | CHF 3.6M | CHF 27.3M | CHF 14.8M | CHF 3.9M | CHF 0.0 |
| Gross profit | CHF 3.6M | −CHF 35.3M | −CHF 39.8M | CHF 3.9M | CHF 0.0 |
| Operating income | −CHF 68.9M | −CHF 52.4M | −CHF 53.6M | −CHF 70.8M | −CHF 79.0M |
| Net income | −CHF 70.4M | −CHF 50.9M | −CHF 54.2M | −CHF 70.8M | −CHF 73.0M |
| Earnings per share | −CHF 0.70 | −CHF 0.51 | −CHF 0.64 | −CHF 0.85 | −CHF 0.97 |
| EBITDA | −CHF 67.8M | −CHF 48.6M | −CHF 51.8M | −CHF 68.0M | −CHF 70.0M |
| Total assets | CHF 154.4M | CHF 230.9M | CHF 182.8M | CHF 185.9M | CHF 261.4M |
| Total debt | CHF 4.5M | CHF 5.4M | CHF 3.5M | CHF 2.8M | CHF 2.9M |
| Cash and short-term investments | CHF 91.4M | CHF 165.5M | CHF 103.0M | CHF 122.6M | CHF 198.2M |
| Shareholders' equity | CHF 44.9M | CHF 112.3M | CHF 160.6M | CHF 169.0M | CHF 232.0M |
| Operating cash flow | −CHF 66.1M | CHF 65.8M | −CHF 60.4M | −CHF 73.6M | −CHF 65.7M |
| Free cash flow | −CHF 67.0M | CHF 65.3M | −CHF 61.2M | −CHF 74.8M | −CHF 68.3M |
| Capital expenditure | −CHF 859.5K | −CHF 576.0K | −CHF 801.0K | −CHF 1.2M | −CHF 2.6M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in CHF; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Alpha Tau Medical | DRTS | $15.09 | $1.36B |
| Alto Neuroscience | ANRO | $26.62 | $934.20M |
| Annexon | ANNX | $4.23 | $692.23M |
| Silence Therapeutics | SLN | $10.92 | $515.89M |
| Contineum Therapeutics | CTNM | $12.96 | $487.57M |
| Amarin | AMRN | $13.13 | $271.56M |
| Lyell Immunopharma | LYEL | $9.70 | $237.69M |
| Cellectis | CLLS | $1.50 | $150.63M |
Peers as grouped by the data provider. This is not an investment recommendation.
Analyst price targets
- Low
- $7.00
- High
- $10.00
- Median
- $8.00
- Consensus
- $8.33
Ratings: 8 buy · 1 hold · 0 sell. Consensus: Buy.
Published sell-side 12-month targets in USD, aggregated by the data provider. They are not Paasa's view and not a forecast.
How to invest in AC Immune from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit.
Step 3
Search ACIU and buy
Find AC Immune by name or by its ticker, ACIU, and place your order. Fractional shares are available and there is no minimum trade size, so you can buy by amount instead of whole shares.
Why invest in AC Immune from India
What AC Immune does
AC Immune S.A. is a biotech firm operating at the clinical stage, dedicated to pioneering, formulating, and advancing therapeutic agents and diagnostic tools. Its core mission is addressing neurodegenerative conditions rooted in protein misfolding, both preventatively and therapeutically. AC Immune operates in the Biotechnology industry within the Healthcare sector.
Hold a dollar asset
AC Immune shares are priced in US dollars, so a weaker rupee adds to what they're worth in rupees. The rupee depreciated over 85% against the dollar between 2010 and 2025.
Buy a fraction of a share
Buy by amount, not by share, and get the matching fraction of one AC Immune share. There is no minimum trade size.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy AC Immune stock from India?
Yes. Indian residents and NRIs can buy AC Immune (ACIU) shares directly through Paasa. AC Immune is listed on NASDAQ, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full AC Immune share?
No. You can buy part of one AC Immune share and add to your position over time. One share is $2.72, and you can buy whole shares or any fraction; there is no minimum trade size.
How are AC Immune dividends taxed for Indian investors?
AC Immune trades on NASDAQ but is domiciled in Switzerland, so any withholding on its dividends follows that country's rules rather than those of the US. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell AC Immune shares?
The US does not levy capital gains tax on shares for Indian residents. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the USD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.